• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

    36.98 -0.37 (-0.98%)
    Streaming Delayed Price Updated: 3:43 PM EDT, Aug 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Teva Pharmaceutical Industries Limited American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    News headline image
    U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
    From Polpharma Biologics International AG
    Via Business Wire
    News headline image
    Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Releases Q2 2026 Aide Memoire
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
    From Alvotech
    Via GlobeNewswire
    News headline image
    Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
    From Alvotech
    Via GlobeNewswire
    News headline image
    Teva to Present at the Goldman Sachs Global Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Present at the BofA Securities Health Care Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
    Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities 
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva Releases Q1 2026 Aide Memoire
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    News headline image
    Teva to Present at the Upcoming Investor Conferences in March
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.